Immuron Ltd (ASX: IMC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Immuron Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.80 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
323.32 million
Earnings per share
-0.023
Dividend per share
N/A
Year To Date Return
-16.67%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Immuron Ltd (ASX: IMC)
Latest News
Share Gainers
Guess which ASX healthcare stock is rocketing 97% on big FDA news
Healthcare Shares
Why the Immuron (ASX:IMC) share price rocketed another 17% today
Healthcare Shares
Here's why the Immuron (ASX:IMC) share price is rocketing 31% today
Healthcare Shares
Immuron (ASX:IMC) share price surges 11% on COVID-19 treatment data
Healthcare Shares
Why the Immuron (ASX:IMC) share price is surging 8% higher
Share Market News
Why the Immuron (ASX:IMC) share price fell today
Share Market News
Why the Immuron (ASX:IMC) share price is rocketing up 10% today
Share Market News
Why the Immuron (ASX:IMC) share price is rocketing 18% higher today
Share Market News
Afterpay and Immuron were among the most traded shares on the ASX last week
Share Market News
Immuron share price falls 27% on registered direct offering
Share Market News
Immuron share price shoots 90% higher on potential COVID-19 treatment news
Share Market News
Immuron share price shoots 6% higher after receiving FDA guidance for new drug
IMC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Immuron Ltd
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
IMC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Feb 2026 | $0.03 | $0.00 | 0.00% | 120,000 | $0.03 | $0.03 | $0.03 |
| 09 Feb 2026 | $0.03 | $0.00 | 0.00% | 207,843 | $0.03 | $0.03 | $0.03 |
| 06 Feb 2026 | $0.03 | $0.00 | 0.00% | 571,707 | $0.03 | $0.03 | $0.03 |
| 05 Feb 2026 | $0.03 | $0.00 | 0.00% | 342,763 | $0.03 | $0.03 | $0.03 |
| 04 Feb 2026 | $0.03 | $0.00 | 0.00% | 734,748 | $0.03 | $0.03 | $0.03 |
| 03 Feb 2026 | $0.03 | $0.00 | 0.00% | 88,264 | $0.03 | $0.03 | $0.03 |
| 02 Feb 2026 | $0.03 | $0.00 | 0.00% | 1,019,798 | $0.04 | $0.04 | $0.03 |
| 30 Jan 2026 | $0.04 | $0.00 | 0.00% | 38,211 | $0.04 | $0.04 | $0.04 |
| 29 Jan 2026 | $0.04 | $0.00 | 0.00% | 950,253 | $0.04 | $0.04 | $0.04 |
| 28 Jan 2026 | $0.04 | $0.00 | 0.00% | 162,037 | $0.04 | $0.04 | $0.04 |
| 27 Jan 2026 | $0.04 | $0.00 | 0.00% | 121,428 | $0.04 | $0.04 | $0.04 |
| 23 Jan 2026 | $0.04 | $0.00 | 0.00% | 225,576 | $0.04 | $0.04 | $0.04 |
| 22 Jan 2026 | $0.04 | $0.00 | 0.00% | 592,450 | $0.04 | $0.04 | $0.04 |
| 21 Jan 2026 | $0.04 | $0.00 | 0.00% | 320,949 | $0.04 | $0.04 | $0.04 |
| 20 Jan 2026 | $0.04 | $0.00 | 0.00% | 6,221 | $0.04 | $0.04 | $0.04 |
| 19 Jan 2026 | $0.04 | $0.00 | 0.00% | 774,601 | $0.04 | $0.04 | $0.04 |
| 16 Jan 2026 | $0.04 | $0.00 | 0.00% | 89,675 | $0.04 | $0.04 | $0.04 |
| 15 Jan 2026 | $0.04 | $0.00 | 0.00% | 661,647 | $0.04 | $0.04 | $0.04 |
| 14 Jan 2026 | $0.04 | $0.00 | 0.00% | 5,373,954 | $0.04 | $0.04 | $0.04 |
| 13 Jan 2026 | $0.04 | $0.00 | 0.00% | 557,579 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Nov 2025 | Paul Brennan | Issued | 1,000,000 | $63,000 |
Issue of options.
|
| 18 Nov 2025 | Daniel Pollock | Issued | 1,000,000 | $63,000 |
Issue of options.
|
| 18 Nov 2025 | Ravi Savarirayan | Issued | 1,000,000 | $63,000 |
Issue of options.
|
| 18 Nov 2025 | Jeannie(Jeannette) Joughin | Issued | 1,000,000 | $63,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Brennan | Non-Executive DirectorNon-Executive Chairman | Mar 2022 |
Mr Brennan is member of Risk Committee. He has experience in the health system through his clinical background and commercial exposure to various multinational companies. Prior to this he was Marketing Director Australia and New Zealand and Sales Director New Zealand for Smith & Nephew Healthcare for six years. He has coordinated marketing, global strategy development, new product development and regulatory processes for the Asia-Pacific region for organisations in relation to medical products and devices. He has knowledge of the manufacturing and production processes.
|
| Mr Daniel Pollock | Non-Executive Director | Oct 2012 |
Mr Pollock is Chair of Risk Committee. He is a sole practitioner in his own legal firm based in Melbourne which operates internationally and specializes in commercial law. Further, he is executive director and co-owner of Great Accommodation Pty Ltd, a property management business operating in Victoria. He has had historical involvement as a seed investor and board member of several small unlisted companies.
|
| Mr Ravi Savarirayan | Non-Executive Director | Apr 2017 |
Mr Savarirayan has been a consultant clinical geneticist at the Victorian Clinical Genetics Services since August 1999, as well as professor and research group leader of Molecular therapies at the Murdoch Children's Research Institute since September 2000. He has served as a founding member of the Skeletal Dysplasia Management Consortium since January 2011 and has acted as the chair of the specialist advisory committee in clinical genetics at the Royal Australasian College of Physicians since February 2009. He was president of the International Skeletal Dysplasia Society from July 2009 to June 2011 and has been an invited member of several international working committees on constitutional diseases of bone.
|
| Dr Jeannie(Jeannette) Joughin | Non-Executive Director | Jun 2024 |
Dr Joughin is a biopharmaceutical and medical device leader with 20 plus years of experience locally and internationally. Her operational and leadership experience has been forged through conducting research at universities and holding clinical and commercial positions of increasing seniority in multi-national pharmaceutical companies, start-up environments in private and listed companies located in the USA, Europe and Australia, and as a Venture Partner working with local and global portfolio companies.
|
| Mr Steven Lydeamore | Chief Executive Officer | Jun 2022 |
-
|
| Ms Olga Smejkalova | Company Secretary | Feb 2026 |
-
|
| Jerry Kanellos | Chief Scientific Officer |
-
|
|
| Flavio Palumbo | Chief Commercial Officer |
-
|
|
| Steven Lydeamore | Chief Executive Officer |
-
|
|
| Olga Smejkalova | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 113,417,824 | 42.29% |
| Authentics Australia Pty Ltd | 5,500,000 | 2.05% |
| Dr Russell Kay Hancock | 4,000,000 | 1.49% |
| Grandlodge Pty Ltd | 3,846,712 | 1.43% |
| Citicorp Nominees Pty Limited | 3,179,722 | 1.19% |
| Mr Iain Chaney & Mrs Antonia Chaney | 2,775,262 | 1.03% |
| Karma Wealth Pty Ltd | 2,500,000 | 0.93% |
| Mr Stephen Anastasiou & Mrs Andria Anastasiou | 2,494,746 | 0.93% |
| Texas Woods Pty Ltd | 2,314,674 | 0.86% |
| Mr Lizhong Yu | 2,100,000 | 0.78% |
| Gravcon Pty Ltd | 2,000,000 | 0.75% |
| Insync Investments Pty Ltd | 2,000,000 | 0.75% |
| Mr Egizio David Bignami | 1,869,887 | 0.70% |
| Miss Ruth Amanda Stroppiana | 1,730,058 | 0.65% |
| Mr Mohammed Akbar Asem | 1,663,731 | 0.62% |
| Mr William David Frank Bird | 1,500,000 | 0.56% |
| Mr Timothy John Noone | 1,407,893 | 0.52% |
| Dr Huy Tran | 1,402,898 | 0.52% |
| Dr Roger Aston | 1,371,376 | 0.51% |
| Mr Anthony Frederick Wallace Hyett | 1,350,000 | 0.50% |
| Mr Peter Anastasiou &Mrs Kristine Patricia Anastasiou Super Fund | 1,332,187 | 0.50% |
